INOZYME PHARMA INC

INZY11 Dec 2024
Healthcare
$2.78
+0.10 (+9.56%)
Lowest Today
$2.75
Highest Today
$3.05
Today’s Open
$2.78
Prev. Close
$2.72
52 Week High
$7.8
52 Week Low
$2.39
To Invest in INOZYME PHARMA INC

INOZYME PHARMA INC

Healthcare
INZY11 Dec 2024
+0.10 (+9.56%)
1M
3M
6M
1Y
5Y
Low
$2.75
Day’s Range
High
$3.04
2.75
52 Week Low
$2.38
52-Week Range
52 Week High
$7.8
2.38
1 Day
-
1 Week
+10.2%
1 month return
-25.56%
3 month return
-43.21%
6 month return
-36.67%
1 Year return
-17.72%
3 Years return
-48.07%
5 Years return
-
10 Years return
-
Institutional Holdings
Adage Capital Partners Gp LLC
8.83
Pivotal bioVenture Partners Investment Advisor LLC
7
Sofinnova Ventures
6.66
Eventide Asset Management, LLC
6.44
Eventide Healthcare & Life Sciences I
6.44
Rock Springs Capital Management LP
5.92
BlackRock Inc
5.2

Market Status

Fundamentals
Market Cap
174.73 mln
PB Ratio
1.99
PE Ratio
0
Enterprise Value
80.28 mln
Total Assets
200.85 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Organisation
INOZYME PHARMA INC
Employees
59
Industry
Biotechnology
CEO
Dr. Douglas A. Treco Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step